AUG 26, 2020 9:07 AM PDT

NAP-6: A Potential Candidate for the Treatment of Breast Cancer

WRITTEN BY: Jasper Cantrell

The body is an amazing and complex system of pathways, all working together in harmony. However, cancer can quickly disrupt this system and turn pathways we rely on for our health against us.

In breast cancer, one of these pathways is the aryl hydrocarbon receptor (AHR) pathway. Usually involved in the breakdown of foreign molecules in the body, its overactivation in breast cancer can impair the DNA repair system and progress cancer even further. A new study from Calvary Mater Newcastle Hospital in Australia shows how a newly developed molecule, NAP-6, strongly inhibits cancer cell growth through its interaction with AHR.

AHR inhibition is already associated with metastasis prevention. The new NAP-6 paradoxically stimulates the AHR pathway, but still somehow suppresses cell growth. Not only that, but NAP-6 could impair the growth of several cancer cell lines while showing low toxicity levels at effective dosage. It even outperformed a similar molecule by two-three fold across the board, suppressing growth in some cell lines to the point where it was negative. 

Analysis of NAP-6 and how it worked showed that it arrested the cell cycle, which usually leads to the cell’s termination. The addition of AHR inhibitors suppressed NAP-6’s effects, confirming its activity was AHR related. The team saw a notable increase in the downstream AHR product CYP1A1 and CYP1A2. The team suggests these proteins are the start of a separate pathway that results in the production of several DNA damaging molecules. NAP-6 is also suggested to be broken down into a carcinogen as well.

As a potential therapeutic, NAP-6 excels in this early study. It manages to induce such a potent inhibition of cancer cell growth, that it actually causes negative growth. These effects were seen in low enough doses not to be toxic to the cells. The exact mechanism has yet to be revealed. Still, the data suggests it may be due to the accumulation of carcinogenic molecules in cancer cells, enough to target it for termination. Moreover, NAP-6 outperformed its competitors in clinical investigations, suggesting great potential for its future as a drug.

The study concludes, “For the first time we have identified the naphthalimide analogue 2-(2-aminophenyl)-1H-benzo[de]isoquinoline- 1,3(2H)-dione (NAP-6) as a potent and selective inhibitor of breast cancer cell growth.”

Sources: Nature Scientific Reports, EmergingScience

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
APR 05, 2021
Cancer
Introducing DeepTCR, the deep-learning software for T-cell receptor sequencing data
APR 05, 2021
Introducing DeepTCR, the deep-learning software for T-cell receptor sequencing data
A team from the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center is introdu ...
MAY 05, 2021
Immunology
Novel 3D Bio-printed Leukemia Model Shows Potential for Treatment Testing Platform
MAY 05, 2021
Novel 3D Bio-printed Leukemia Model Shows Potential for Treatment Testing Platform
Three-dimensional (3D) printing has become a common technique over the past two decades. Now, the technique has been ado ...
MAY 16, 2021
Cancer
Can you guess which drug is both antiviral and immunotherapeutic?
MAY 16, 2021
Can you guess which drug is both antiviral and immunotherapeutic?
Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths ...
JUN 07, 2021
Health & Medicine
Higher Incidence of Breast Cancer in Polluted Urban Areas
JUN 07, 2021
Higher Incidence of Breast Cancer in Polluted Urban Areas
A Taiwanese study looked at the incidence of breast cancer in areas of Taiwan with varying levels of air pollutants. Air ...
JUN 18, 2021
Cancer
Cancer cell lines are too dissimilar from human cancer cells
JUN 18, 2021
Cancer cell lines are too dissimilar from human cancer cells
A new study finds cultured cancer cells lack genetic similarity to humans. This is concerning because cancer cell lines ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
Loading Comments...